- Home
- AUTL vs EYPT Comparison
AUTL vs EYPT Comparison
Compare AUTL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | EYPT |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 1.1B |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AUTL | EYPT |
|---|---|---|
| Price | $1.27 | $11.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.50 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 03-27-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,120,000.00 | $7,539,000.00 |
| Revenue This Year | $85.73 | N/A |
| Revenue Next Year | $70.87 | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $3.91 |
| 52 Week High | $2.70 | $19.11 |
Technical Indicators
Market Signals| Indicator | AUTL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 32.82 |
| Support Level | $1.23 | $11.21 |
| Resistance Level | $1.52 | $12.24 |
| Average True Range (ATR) | 0.07 | 0.77 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 22.35 | 0.65 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.